New combo therapy aims to control advanced lung cancer
NCT ID NCT03527108
First seen Jan 20, 2026 · Last updated May 08, 2026 · Updated 13 times
Summary
This study tests a combination of two drugs, nivolumab and ramucirumab, in people with advanced non-small cell lung cancer that has come back or spread. Participants have already received immunotherapy. The main goal is to see if the combination can control the disease by shrinking tumors or keeping them stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
NYU Langone
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.